spacer
home > pmps > winter 2018 > patience with patients
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Patience with Patients

What is patient adherence?

As defined by the WHO, patient adherence is the extent to which a personís behaviour Ė for example, taking medication, following a diet or executing lifestyle changes Ė corresponds with the agreed recommendations from a healthcare provider. A low level of adherence means that the likelihood of patients taking their prescribed medication correctly is small, which can be very dangerous, in some cases.

Would you say that this is a growing or lessening concern for the pharmaceutical industry and why?

Patient adherence is currently one of the biggest challenges that the pharma industry is facing and remains a growing concern. Not only do low patient adherence levels affect healthcare efficacy, it is also extremely costly to the industry. Research shows that patients not taking their medication in line with recommendations costs the NHS £500 million per year, which, in context, is equivalent to 30,000 kidney transplants or an extra 21,000 qualified nurses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rupert Taylor joined Essentra in 2014 as Global Category Manager Household for food and drink. He is now Global Category Manager for healthcare and personal care. Rupertís role is to identify customer and consumer needs in the market place and deliver those solutions through the companyís portfolio of packaging, components, special technologies, security, and authentication. Prior to joining Essentra, he worked as Marketing and Innovation Director for Puratos, Brazil. Rupertís experience spans over 20 years in delivering results in both B2B and B2C environments on a global basis.
spacer
Rupert Taylor
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Expands Services for Early Discovery Screening

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharmaceutical and biotechnology hubs.
More info >>

White Papers

Industrial Security in the Pharmaceutical Sector

COPA-DATA

As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>

 
Industry Events

Clinical Trial Supply Nordics 2018

19-20 June 2018, Copenhagen, Denmark

Building on last yearís success, our CTS team have conducted extensive research to ensure the 2018 event programme covers all the essentials in clinical supply. In the current climate, every pharma and biotech company are trying to reduce unwanted costs, and enhance operational efficiency. To avoid costly setbacks, an innovative and effective strategy needs to be implemented!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement